DNP Project: Reversal of Neuromuscular Blockade with Neostigmine: Development of an Evidence-based Practice Protocol by Mayer, Kyle L
DePaul University 
Via Sapientiae 
College of Science and Health Theses and 
Dissertations College of Science and Health 
Summer 8-21-2016 
DNP Project: Reversal of Neuromuscular Blockade with 
Neostigmine: Development of an Evidence-based Practice 
Protocol 
Kyle L. Mayer 
DePaul University, mayerkyle427@hotmail.com 
Follow this and additional works at: https://via.library.depaul.edu/csh_etd 
 Part of the Nursing Commons 
Recommended Citation 
Mayer, Kyle L., "DNP Project: Reversal of Neuromuscular Blockade with Neostigmine: Development of an 
Evidence-based Practice Protocol" (2016). College of Science and Health Theses and Dissertations. 150. 
https://via.library.depaul.edu/csh_etd/150 
This Dissertation is brought to you for free and open access by the College of Science and Health at Via Sapientiae. 
It has been accepted for inclusion in College of Science and Health Theses and Dissertations by an authorized 
administrator of Via Sapientiae. For more information, please contact digitalservices@depaul.edu. 
 Running head: NEOSTIGMINE 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reversal of Neuromuscular Blockade with Neostigmine:  
Development of an Evidence-based Practice Protocol 
Kyle L Mayer 
DePaul University 
Chicago, IL 
 
 
 
 
  
NEOSTIGMINE 2
Abstract 
Background/Significance: A large population of patients entering the post-operative anesthesia 
care unit (PACU) with residual neuromuscular blockade (NMB), as defined by a Train-of-Four 
ratio < 0.9, has been reported in the literature.  Patients with residual NMB have a higher 
likelihood of respiratory insufficiency and failure, and many others experience uncomfortable 
feelings of muscle weakness. Neostigmine is a commonly used agent to reverse NMB, but little 
is known about factors which affect use and dosing.   
Purpose/Objectives: The purpose of this Scholarly Leadership Project was to identify the 
factors being considered by anesthesia providers when using neostigmine as a reversal agent for 
NMB. The findings from this study and current evidence were utilized in the formulation of a set 
of evidence-based practice guidelines for the reversal of NMB with neostigmine.    
Design: This study utilized a descriptive, online survey design.  
Methods: A survey was sent through the email LISTSERV of the Illinois Association of Nurse 
Anesthetists (IANA), the official professional organization of certified registered nurse 
anesthetists (CRNAs) in the state of Illinois.192 active CRNA members of the IANA 
participated.  A validated, investigator-developed online survey, which examined the factors 
being considered by anesthesia providers when using neostigmine, was sent to 1,384 members of 
the IANA. 
Analysis: Descriptive statistics using means, standard deviation, frequencies, and percentages 
was used to describe the sociodemographics of respondents and the online responses to the 
survey.  Chi square statistics were utilized to examine different factors considered by CRNAs 
when administering neostigmine. 
Findings: This study revealed different factors that anesthesia providers consider when using 
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neostigmine including: quantity and quality of muscle twitches present during train-of-four 
monitoring, twitches with and without fade, and time elapsed since the last dose of 
neuromuscular blocking agent.  Furthermore, no statistically significant differences were found 
in the mean score of the factors being considered for neostigmine use between CRNAs in terms 
of their years of experience, types of practice, institutional settings, and level of education. 
Practice Implications: Project results provide an evidence-based practice protocol, which 
anesthesia providers can use in discerning adequate and appropriate reversal of NMB. 
Keywords: Neuromuscular blockade, neuromuscular blocking agents, neostigmine, residual, 
reversal   
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Section I: Introduction 
Background and Significance 
 Non-depolarizing muscle relaxants (NDMR)  are agents, which cause temporary 
musculoskeletal paralysis through competitive inhibition of acetylcholine at the motor end plate 
(Butterworth, Mackey, & Wasnick, 2013b).  Intraoperative use of NDMRs allows for reliable, 
reversible muscle relaxation, which facilitates surgical access to the operative site.  Drugs that 
reverse the effects of NDMRs are known as cholinesterase inhibitors (Kruidering-Hall & 
Campbell, 2012).  Cholinesterase inhibitors that are currently available include neostigmine, 
edrophonium, pyridostigmine, and physiostigmine, with neostigmine and edrophonium being the 
most commonly used in anesthesia practice in the United States.  This study focused only on 
neostigmine. 
Neostigmine is a common agent used to reverse the effects of NDMRs through inhibition 
of the enzyme, acetylcholinesterase (Butterworth, Mackey, & Wasnick, 2013a).   Through 
inhibition of acetylcholinesterase, acetylcholine (ACh) levels increase, which results in the 
stimulation of both nicotinic and muscarinic receptors (Butterworth, Mackey, & Wasnick, 
2013a).  Nicotinic receptors are found in the neuromuscular junction of skeletal muscles and 
increased stimulation of these receptors results in stronger contractions of muscle fibers 
(Pappano, 2012).  Conversely, muscarinic receptors are found in mucous membranes, lining of 
the lungs, atrioventricular (AV) node of the heart, eyes, and central nervous system (Pappano, 
2012).  Stimulation of muscarinic receptors by ACh results in bradycardia, prolongation of the 
QT interval, increased mucous secretion, bronchoconstriction, pupillary constriction, and smooth 
muscle contraction of the intestines and bladder (Butterworth, Mackey, & Wasnick, 2013a).  
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Glycopyrrolate, an anti-muscarinic agent, is routinely administered concomitantly with 
neostigmine, which abates the side effects associated with muscarinic agonism (Butterworth, 
Mackey, & Wasnick, 2013a). 
 Within the practice of anesthesia there is a wide variance in the dosing and administration 
practices of neostigmine (Duvalestin, Cunin, Plaud, & Maison, 2008; Gray & Wilson, 1959; 
Naguib et al., 2010; Videira & Vieira, 2011).  Anesthesia providers often base dosing 
preferences on several factors that include age, quality of muscle relaxation, timing of the last 
administration of NDMR, disease processes affecting drug metabolism and excretion, such as 
liver and kidney disease).  Currently, there are no universally accepted guidelines for reversal of 
neuromuscular blockade with neostigmine.  Moreover, several published articles have called for 
the development of a set of guidelines for NMB reversal based on the negative effects of residual 
NMB (Cedborg et al., 2014; Saur, Stahn, Soltesz, Noeldge-Schomburg, & Mencke, 2011; 
Sundman, et al., 2000).  A synthesis of the adverse effects of residual NMB can be found in 
Table 1.   
 Neuromuscular monitoring allows the anesthesia provider to assess the status of muscle 
paralysis through electrical stimulation of nerve fibers.  Train-of-four (TOF) neuromuscular 
monitoring consists of four separate electrical impulses delivered at intervals of 0.5 seconds, 
which in non-paralyzed will result in four brief muscle contractions, also known as twitches 
(Dorsch & Dorsch, 2011).  The number and intensity of twitches obtained is correlated to the 
intensity of the neuromuscular block.  Train-of-four ratio (TOFR) compares the amplitude of the 
fourth muscle twitch divided by the amplitude of the first muscle twitch (Dorsch & Dorsch, 
2011).  A TOFR of 1 (100%) signifies the absence of NMB.  Conversely, a lower TOFR 
signifies a more intense NMB (Dorsch & Dorsch, 2011). 
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 According to Murphy and Brull (2010), 40% of postoperative patients whom received 
intraoperative muscle relaxation have residual NMB with a train-of-four (TOF) ratio < 0.9 and 1-
3% will experience an adverse event due to residual paralysis.  A study by Debaene, Plaud, Dilly, 
& Donati (2003) identified 45% of postoperative patients had residual neuromuscular blockade 
after receiving a single dose of intermediate-acting NDMR.  Cedborg et al. (2014) identified an 
increased incidence of pharyngeal dysfunction in patients with partial NMB, resulting in 
aspiration.   
Problem Statement 
 A wide variation exists among anesthetists in the dosing and administration of NMB  
reversal agents.  Additionally, no universally published guidelines exist for the reversal of NMB.  
As a result of the large variation in dosing and administration of NMB reversal agents, a 
significant number of post-operative patients have residual NMB.  Patients with residual NMB 
may experience hypoventilation, leading to hypoxia, and possible apnea (Kruidering-Hall & 
Campbell, 2012).   
Study Purpose 
 This project identified the factors in which anesthesia providers currently use to dose and 
administer neostigmine and examine the types of neuromuscular monitoring used by CRNAs 
during the reversal of NMB using neostigmine.  The findings from this study can aid in the 
development of an evidence-based practice protocol for the reversal of NMB using neostigmine.  
This study aimed to answer the following research questions: 
1. What factors do anesthesia providers consider when administering neostigmine? 
2. What are the significant factors that anesthesia providers use to determine neostigmine 
dosing? 
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3. What are the types of neuromuscular monitoring are used by anesthesia providers during 
the reversal of NMB using neostigmine? 
4. Are there significant differences in the factors considered by anesthesia providers 
according to practice type (academic versus non-academic practice), years of experience 
(less than 5 years versus 5 years of more), level of education (Bachelors versus Masters 
versus Doctoral degree), and type of institution in which anesthesia is practiced. 
Conceptual Framework 
 The conceptual basis for the development of an evidence-based practice (EBP) protocol 
for safe NMB reversal and implementing the protocol into the practice of anesthesia providers is 
consistent with the Stetler model of Evidence-based Practice.  The model is grounded in the 
conceptual framework of research utilization (RU), which according to Stetler (2001), “is the 
process of transforming research knowledge into practice” (p. 282).  Furthermore, RU dominates 
the early steps of the Stetler model, and results in the acceptance of evidence-based practice 
found in the latter stages of the model (Stetler, 2001).   
 The Stetler model of evidence-based practice, describes five phases of how practitioner 
analyze and use study findings to implement evidence-based nursing practice change (Dang et al., 
2015).  As described by Stetler (1994; 2001) the five phases are as follows: 
 Phase I: Preparation.  During the preparation phase the practitioner defines the purpose 
and outcomes for each issue (Stetler, 2001).  In addition, influencing factors (i.e. internal, 
external), which may interfere with research progress or validity, should be identified (Stetler, 
2001).  Furthermore, various sources of research evidence are collected and sorted. 
 Phase II: Validation.  During the validation phase the practitioner evaluates evidence in 
the form of a critique and synopsis (Stetler, 2001).  Furthermore, sources are rated based on the 
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strength of the findings (Stetler, 2001).  If sufficient evidence exists the researcher moves into 
phase III of the model (Stetler, 1994).  Conversely, if there is insufficient evidence the study 
ends at phase II (Stetler, 1994). 
 Phase III: Comparative evaluation/Decision making.  During the comparative 
evaluation or decision making phase the practitioner uses a set of four criteria to determine if 
study findings can be applied to practice (Stetler, 1994).  First, the “fit of setting” criterion 
allows the researcher to investigate similarities between the sample and the study setting, and the 
population and setting of which EBP is being implemented (Stetler, 2001).  Second, the 
“feasibility: r, r, r” criterion assesses the risk, resources, and readiness for implementation of 
EBP (Stetler, 2001).  Third, the “current practice” criterion assesses the effectiveness of current 
practice and the relevance for EBP in the current practice (Stetler, 1994).  Fourth, the 
“substantiating evidence” criterion assesses the overall strength of the research evidence (Stetler, 
2001).  Evidence is then labeled as either “to not use,” “to use,” or “to consider use” (Stetler, 
2001, p. 277).  If the evidence is labeled “to use” or “to consider use” the pracitioner progresses 
to phase IV, however if the evidence is labeled “to not use” the study is stopped (Stetler, 2001). 
 Phase IV: Translation/application.  The translation or application phase focuses on the 
integration of the developed EBP (Stetler, 2001).  The research findings are converted into 
practice change or recommendations (Dang et al., 2015).  
 Phase V: Evaluation.  During the evaluation phase the pracitioner assesses the various 
outcomes of the practice change (Stetler, 2001).   
 The use of a theoretical framework helped to guide planning and implementation stages 
of the Scholarly Leadership Project.  The Stetler model of evidence-based practice as developed 
by Stetler (1994; 2001) enhances the strength of the evidence-based guidelines for 
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neuromuscular blockade reversal using neostigmine by guiding the acquisition and application of 
evidence.  Phase V, evaluation, will not be conducted in this project, however evaluation of 
protocol dissemination may be the focus of follow up studies.  
Section II: Literature Review 
 A search of the literature regarding neostigmine dosing and administration, and the 
incidence of neuromuscular blockade was conducted.  The literature search was performed using 
the following computerized databases: Web of Science, PubMed, and ScienceDirect.  The 
following Medical Subject Heading (MeSH) terms “ neuromuscular blockade” and “neostigmine” 
plus common search term, "residual" were utilized during the computer-based literature search.  
The search results were filtered by removing studies that contained the term “sugammadex” as 
this NMB reversal agent lacked FDA approval at the time the literature review was written and is 
not included in the subject of this study.  The database search generated 290 articles.  Journal 
articles included in the literature review were scholarly papers meeting the following criteria: 
demonstrated a knowledge deficit in the area of neuromuscular block (NMB) reversal; contained 
information that is important in the creation of best practice guidelines and/or objectives aimed at 
improving practice and patient outcomes. 
Residual Neuromuscular Blockade 
 Incidence.  Residual neuromuscular blockade is defined as a train-of-four ratio (TOFR) < 
0.9.  A study performed by Murphy et al. (2005) demonstrated that the vast majority of patients 
(87.5%) have residual NMB immediately before tracheal extubation despite passing standard 
methods of extubation criteria - TOF 4/4 without fade (incremental decrease in the amplitude of 
each consecutive twitch), eye opening, adequate spontaneous ventilation, and five-second head 
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lift or hand grasp.  The findings of this study suggest that the standard methods of evaluating the 
effectiveness of NMB reversal are ineffective in identifying residual NMB. 
 Several similar studies have demonstrated the presence of residual NMB, which 
progressed into the postoperative phase of recovery.  In a study by Gaszynski, Szlachcinski, 
Jakubiak, and Gaszynski (2009), 48% of patients entering the post-anesthesia care unit (PACU) 
had residual NMB (TOF Ratio <0.9).  Furthermore, 26% of the patients had a TOF ratio less 
than 0.7.  Adamus, Koutna, and Neoral (2007) performed a study in which no neuromuscular 
monitoring was used during the anesthetic.  The study demonstrated a 34% incidence of residual 
neuromuscular blockade upon arrival to the PACU.  The researchers compared the patients with 
postoperative residual NMB to those that had fully recovered; they discovered that the patients 
with residual NMB received larger doses of rocuronium, given less neostigmine, and there was 
less time between the last dose of rocuronium and the administration of neostigmine.  
 Sauer, Stahn, Soltesz, Noeldge-Schomburg, and Mencke (2011) conducted a study in 
which one group received a standardized weight-based dose of neostigmine and the other 
received a placebo.  Patients who received neostigmine were allowed to return to a TOF ratio of 
1.0 before tracheal extubation, whereas the placebo group were tracheal extubated at a TOF ratio 
less than 1.0, but without fade in TOF and double-burst nerve stimulation. Double-burst 
stimulation is a set of three electrical stimuli at 50 Hz followed by another set of two or three 
electrical stimuli timed 0.75 seconds later.  Fifty-percent of the placebo group developed 
hypoxemia, compared to 28% in the neostigmine group.  This study demonstrated that 
neostigmine was effective in antagonizing rocuronium versus placebo, however a large 
population of patients still developed adverse respiratory outcomes despite full reversal of NMB. 
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 Complications.  The diaphragm is a skeletal muscle therefore NMBAs impair diaphragm 
excursion.  Impairment of diaphragm may result in shortness of breath, atelectasis (collapse of 
alveoli resulting in intrapulmonary shunting), respiratory distress, or respiratory failure.  
Furthermore, skeletal muscles are involved in swallowing, movement of the vocal cords, 
epiglottis, and tongue, and for stenting open the structures of the upper airway (i.e. 
laryngopharynx, oropharynx, and nasopharynx).  For patients with neuromuscular paralysis the 
anesthesia provider is tasked with controlling ventilation, and protecting the airway from 
aspiration.  Therefore it can be hypothesized that a patient with residual NMB may also require 
airway management to maintain adequate ventilation and to prevent aspiration.  In fact, a study 
by Eikermann et al. (2007) demonstrated that patients with partial NMB have decreased upper 
airway volumes during inspiration.  Additionally, expiratory volume and respiratory rate were 
not affected by partial NMB (Eikermann et al., 2007).  In a similar study, Eriksson et al. (1997) 
demonstrated that patients with partial neuromuscular paralysis had a higher likelihood of 
aspiration due to pharyngeal dysfunction if the TOFR was less than 0.9.  In fact, six out of 14 
volunteers aspirated with a TOFR less than 0.9, while no volunteers aspirated with a TOFR 
greater than 0.9 (Eriksson et al., 1997). 
 Cedborg et al. (2014) performed a study involving elderly patients with partial 
neuromuscular paralysis and the inability to protect their airway from aspiration.  They 
concluded that partial neuromuscular paralysis increases pharyngeal dysfunction with aspiration 
from 37% (control) to 71% (study).  A similar study by Sundman et al. (2000) compared the 
incidence of pharyngeal dysfunction in a control group with patient with partial neuromuscular 
paralysis at TOFR 0.6, 0.7, 0.8 and 0.9.  The control group had a pharyngeal dysfunction rate of 
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6% compared to 28% at a TOFR of 0.6; 17% at a TOFR of 0.7; 20% at a TOFR of 0.8; and 13% 
for patients with a TOFR greater than 0.9 (Sundman et al., 2000).   
Neostigmine 
 Administration.   Studies have demonstrated that the majority of anesthesia providers do 
not routinely reverse NMB (Naguib et al., 2010; Osmer, Vogele, Zickman, & Hempelman, 1996).   
However current studies recommend the routine reversal of NMB (Miller & Ward, 2010; 
Kopman & Eikermann, 2009).  However, if objective neuromuscular monitoring can 
demonstrate a TOFR ≥ 0.9 neostigmine is not reccomended, nor is it required (Lien, 2010). 
 When administrating neostigmine to reverse NMB the goal is to time the dose of the 
reversal agent so that the peak effect of the drug occurs closely before tracheal extubation.  
Buder et al. (2010) concluded that a reduced dose of neostigmine adequately reverses a shallow 
NMB (TOFR > 0.4) caused by atracurium within 10 minutes.  Murphy (2006) suggests 
practitioners are administering the reversal agent too late and thus not allowing sufficient time 
for the reversal agent to act.  Furthermore, full reversal of an intense NMB may require 20-30 
minutes, and thus Brull & Murphy (2010) recommends reversal be given 15-30 minutes before 
tracheal extubation.   
 Dosing.  The standard dosing of neostigmine when reversing NMB is 25-75 mcg/kg 
(Nagelhout, 2014).  A study by Buder et al. (2010) evaluated the dose-effect relationship of 
neostigmine.  Results of the study determined the NMB recovery time from the start of the 
neostigmine administration to a TOFR of 0.9 and 1.0 with starting TOFR of 0.4 and 0.6 (Buder, 
2010).  NMB recovery time for a starting TOFR of 0.4 to an end point of TOFR 0.9 are as 
follows: six minutes for a neostigmine dose of 10 mcg/kg, six minutes for a neostigmine dose of 
20 mcg/kg, and four minutes for a neostigmine dose of 30 mcg/kg (Buder, 2010).  NMB 
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recovery time for a starting TOFR of 0.6 to an end point of TOFR 0.9 are as follows: four 
minutes for a neostigmine dose of 10 mcg/kg, three minutes for a neostigmine dose of 20 mcg/kg, 
and four minutes for a neostigmine dose of 30 mcg/kg (Buder, 2010).  Furthermore, the 
probability of successful reversal within 10 minutes of neostigmine administration increased as 
the dosage increased with 30 mcg/kg near 100% at TOFR of 0.4 and 0.6 (Buder, 2010).  These 
results suggest that moderate degrees of NMB may be adequately antagonized with neostigmine 
dosages of 20 – 30 mcg/kg.  There is a lack of research for a dose-effect relationship at higher 
intensity of NMB.  
 Age.  It is a well known that pharmacokinetics and pharmacodynamics vary significantly 
across the age spectrum and should be given special consideration when dosing neostigmine.  A 
study by Bevan et al. (1999) demonstrated significant variation between adults, aged 20-65 years 
old, and children, aged 2-12 years old, in the recovery time from NMB after reversal with 
neostigmine.  Children with NMB due to rocuronium administration recovered to a TOFR of 0.9 
in 12.1 minutes versus adults who recovered in 37.1 minutes when neostigmine is administered 
five minutes after relaxant (Bevan et al., 1999).  However, when neostigmine is administered 
with a TOFR of 0.25, children recovered from NMB from rocuronium in 4.8 minutes versus 
adults who recovered in 4.5 minutes (Bevan et al., 1999).  This study demonstrates that age is an 
important factor when reversing an intense NMB as evidenced by the large age group variation 
in time when neostigmine was administered five minutes after NDMR.  However, if reversing 
when a TOFR is ≤ 0.25 it seems age becomes less of a factor. 
 Body Composition.  Studies have shown that obesity increases the duration of NMB 
(Schwartz, Matteo, Ornstein, & Halevy, 1992; Weinstein et al., 1988).  As a result of these study 
conclusions, it could be hypothesized that obesity also affects the reversal of NMB.  In fact, a 
NEOSTIGMINE 16
study by Suzuki, Masaki, & Ogawa (2006) demonstrated that obese patients with NMB reversed 
by neostigmine required a significantly longer time to reach a TOFR of 0.9 in comparison with 
the normal weight and overweight patient populations.  In fact, obese patients required 25.9 
minutes to obtain a TOFR of 0.9, whereas overweight patients required 14.6 minutes and normal 
weight patients required only 6.9 minutes (Suzuki, Masaki, & Ogawa, 2006).  The results from 
this study demonstrate that the obese patient requires a significantly longer time to recover from 
NMB and thus the anesthesia provider should consider early administration of neostigmine. 
Monitoring 
 Neuromuscular monitoring is essential for effective reversal of NMB.  Without the use of 
monitoring the anesthesia provider is blindly administering additional muscle relaxant and 
reversal agent.  Despite the importance of neuromuscular monitoring several studies have 
demonstrated that a large number of anesthesia practitioners do not routinely use neuromuscular 
monitoring in their practice (Grayling & Sweeney, 2007; Sorgenfrei, Mogensen & Swiatek, 
2005; Buder et al, 2003).  Brull and Murphy (2010) assert, “perioperative monitoring of evoked 
neuromuscular responses that guides the administration of anticholinesterases and documents 
return of neuromuscular function should be a standard of care” (p. 135).  
 Qualitative or subjective nerve monitoring uses an electrical impulse to stimulate an 
evoked potential along a peripheral motor nerve, which results in a brief contraction or twitch of 
the muscle that the nerve innervates.  The anesthesia provider observes the muscle twitch and 
notes the quality (fade versus no-fade) and the quantity (twitch count).  Peripheral nerves 
commonly used for twitch monitoring include the facial, ulnar, and tibial nerves, however 
reliability of twitch monitoring varies amongst the nerves.  Thilen et al. (2012) concluded that 
train-of-four nerve monitoring of the facial nerve was associated with a higher incidence of 
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residual neuromuscular block when compared to nerve monitoring at the ulnar nerve (incident 
rate of 52% versus 22% respectively).  Thus, the ulnar nerve is the preferred site for qualitative 
(subjective) nerve monitoring. 
 Monitoring of clinical signs is a common method used by practitioners to assess for 
residual NMB.   These clinical signs include patient responsiveness, subjective measurements of 
muscle strength (i.e. 5-second head lift, hand grasp), eye opening, and tongue extrusion, however 
studies have demonstrated these tests do not reliably predict adequate reversal of neuromuscular 
blockade (Eikermann, Groeben, Hussing, & Peters, 2003; Hayes, Mirakhur, Breslin, Reid, & 
McCourt, 2001; Fruergaard, Mogensen, Berg, & El Mahdy, 1998; Mogensen & Claudius, 2010).  
According to Grayling & Sweeney (2007), the majority of anesthesia providers primarily rely on 
clinical signs when assessing the status of neuromuscular blockade. 
Section III: Methods 
Design 
 This study utilized a descriptive, online survey design. 
Setting 
 The online survey was distributed to all certified registered nurse anesthetists (CRNAs) 
who are members of the Illinois Association of Nurse Anesthetists (IANA), the official 
professional organization of CRNAs in the state of Illinois. 
Sample 
 The sample for this study included CRNAs who are members of the IANA.  Student 
registered nurse anesthetists (SRNAs) were excluded from this study whether members of the 
IANA or not.  Additionally, anesthesiologists and anesthesia residents were excluded from the 
survey by means of the survey distribution. 
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Sample Size 
 There are approximately 1,384 CRNA members of the IANA.  A convenience sampling 
of the population described above was utilized in this study.  Online surveys can have a wide 
range of responsiveness.  Based on a study by Cook, Health, and Thompson (2000), an average 
30% response rate was found when 39 separate online surveys were analyzed (Pan, 2010). 
Therefore, for this study the targeted response rate was 30%.  The number of complete responses 
was 192 (13.7%).   
Recruitment Procedure 
 The subjects for this study were CRNAs recruited from the IANA.  Institutional Review 
Board (IRB) approval was obtained from DePaul University.  A form letter was emailed to the 
administrator of IANA requesting to send out the web link for the online Qualtrics survey to all 
CRNAs (Appendix A).  The IANA distributed the survey to all CRNA members by means of an 
email LISTSERV.  A web link in the email directed the study participant to the anonymous 
online Qualtrics survey.  The email template used for survey dissemination by the IANA can be 
found in Appendix B. 
 Test-retest reliability was conducted using a subgroup of CRNAs who volunteered to 
retake the survey by providing their email address to determine the reliability of the investigator-
developed online survey.  An email with the survey retest link was sent to all volunteers and a 
reminder email was sent two weeks later.  A total of 44 CRNA volunteers responded, however 
only 28 CRNAs completed the retest survey.  
 
 
NEOSTIGMINE 19
Instrument 
 The instrument included brief demographic questions and an investigator-developed 
online survey that examined the factors that are considered by anesthesia providers when using 
neostigmine as a reversal agent for NMDR such as the age, gender, and weight of patients among 
others (Appendix C).  The survey questions were related to neostigmine administration practices 
among CRNAs.  The demographic questions of the survey included years of experience, 
education level, type of institution and practice type (academic or non-academic).  Face validity 
of the survey tool was established through the review of the survey questions by ten content 
experts including CRNAs and attending anesthesiologists.  Content validity was established 
through a comprehensive literature review on the content domains of neostigmine use.  
Reliability of the survey was established using test-retest reliability testing using Pearson's r 
correlation statistics. A Pearson's r value of .70 or greater indicates adequate reliability of the 
online survey. The reliability of the survey was established by sending the survey twice at one-
week intervals to only those participants who volunteered to complete the test-retest.  
Human Subjects Protection 
 Training of Research Personnel on Human Subject Protections was completed May 19, 
2015.  The researcher of this study completed the following Collaboratve Institutional Training 
Initiative (CITI) courses: CITI Health Information Privacy and Security (HIPS) for students, 
Responsible Conduct of Research, and Students – Class Projects.  Approval was received from 
the DePaul IRB on November 23, 2015 (Appendix F). 
 The study survey was distributed to CRNA members of the IANA via an email from the 
IANA.  Informed consent was implicit through volunatary completion of the survey.  Survey 
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responses were collected anonimously via Qualtrics and no IP addesses were associated with the 
collected surveys.  Data will be destroyed three years after study completion.   
Analysis 
 Descriptive statistics were used to describe the sociodemographics of respondents and the 
online responses to the survey.  Chi square statistics were performed to examine significant 
differences in the factors considered by anesthesia providers when administering neostigmine.  
Dichotomous, independent groupings (academic versus non-academic practice type, low level of 
years of clinical experience less than five years versus clinical experience of five years or more, 
lower level of education with Bachelor’s degree versus higher level of education with Doctoral 
degree) of CRNAs were used in the analysis.  
Project Design 
 Assessment.  In the assessment phase, an electronic survey was distributed to the target 
population to collect demographic data and obtain data related to the current practices of 
reversing NDMRs with neostigmine.  A Practice protocol for reversing NDMRs using 
neostigmine was developed utilizing the study results and the information obtained through the 
review of the literature.  
 Implementation.  In the implementation phase, a practice protocol for reversal of 
NDMRs using neostigmine will be developed and submitted to the IANA and/or the American 
Association of Nurse Anesthetists (AANA) for white paper consideration.   
 Evaluation.  This study leaves the evaluation process of the practice protocol for future 
research.  A future study could evaluate practice change among the anesthesia providers by 
submitting a follow-up survey after implementation of the NDMR reversal protocol.  The study 
could be expanded to include attending anesthesiologists, anesthesia residents, and SRNAs to 
NEOSTIGMINE 21
analyze variance in dosing and administration of neuromuscular blockade reversal amongst the 
groups. 
Section IV: Findings 
Survey Tool 
 In order to determine content validity the survey was graded by 10 content experts 
consisting of six CRNAs and four physician anesthesiologists. The experts comprehensively 
graded each of the three categories: “factors for use,” factors for dosing,” and “neuromuscular 
monitoring.”  In addition, the content experts graded the individual survey questions.  The 
questions that were graded were specific to the practice of reversing neuromuscular blockade 
(Neostigmine Factors Scale) using questions six through 19, and thus excluding questions related 
to demographics, provider readiness for practice change, and questions regarding survey 
retesting for validity.  Each item was graded for clarity, relevance, simplicity, and consistency 
using a 10-point Likert-type scale.  
 Clarity: score of 1 = unclear, score of 10 = very clear 
 Relevance: score of 1 = not relevant, score of 10 = high relevance 
 Simplicity: score of 1 = very complex and confusing, score of 10 = simple and 
easy to understand 
 Consistency: score of 1 = inconsistent, score of 10 = high consistency 
The results revealed a statistically significant correlation between survey grades by content 
experts (r = 0.913, p < 0.000), therefore providing sufficient evidence of survey content validity. 
  
NEOSTIGMINE 22
Table 2. Content Validity 
Numbers expressed as Average Score 
 
Domains Clarity 
 
Relevance 
 
Simplicity 
 
Consistency 
 
1. Factors for 
Use 
 
10 8.8 10 9.6 
2.  Factors for 
Dosing 
 
10 9.5 10 9.9 
3. 
Neuromuscular 
monitoring 
 
9.9 9.3 10 10 
 
 Questionnaire 
Item Number 
Q
1 
Q
2 
Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
Q
9 
Q1
0 
Q1
1 
Q1
2 
Q1
3 
 Domain 1 1 1 1 1 1 2 2 2 3 3 3 3 
Clarity  9.
9 
10 9.
5 
9.
9 
9.
7 
9.
9 
10 9.
8 
9.
5 
10 9.6 9.6 9.3 
Relevance  9.
2 
9.
8 
9.
3 
9.
5 
9.
5 
9.
9 
10 9.
5 
9.
5 
10 9.7 9.8 9.6 
Simplicity  10 10 9.
5 
10 10 10 10 9.
9 
9.
5 
10 9.8 9.8 9.8 
Consistency  10 10 9.
3 
10 10 10 10 10 9.
5 
10 9.8 9.8 9.8 
 
Clarity: score of 1= unclear up to a score of 10 = very clear question items. 
Relevance: score of 1 = not a relevant question items up to a s core of 10 = highly relevant 
question items 
Simplicity: score of 1 = very complex, confusing question items up to a score 10 = simple, easy 
to understand question items  
Consistency: score of 1 = inconsistent question items up to a score of 10 = highly consistent 
question items   
 
 Survey tool reliability.  Reliability of the online survey tool was tested using the results 
from survey questions six through 19 (Neostigmine Factors Scale). The results revealed the 
survey tool was reliable in measuring the opinions of CRNA on the various factors influencing 
the use of neostigmine (Cronbach's alpha = 0.711). Additionally, test-retest was also performed 
to measure the reliability of the online survey. A total of 44 CRNAs volunteered to complete a 
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retest survey, however only 28 participants completed the retest, which contained identical 
survey questions to that of the original survey.  Using the Pearson intraclass correlation 
coefficient test the results of the original survey were correlated with the results of the retest. A 
statistically significant correlation was revealed between the two surveys (r = 0.84, p < 0.000), 
thereby providing adequate evidence of test-retest reliability. 
Descriptive Statistics 
 Complete survey results were collected from 192 (13.9%) out of 1,384 CRNA members 
of the IANA.  Survey completion was voluntary and all participants met the inclusion criteria.  
Each subject completed an online survey regarding factors used when dosing and administering 
neostigmine for reversal of neuromuscular blockade.  The majority of the participants had >20 
years (n=53, 27.6%) of experience as a CRNA, 23.4% had 0-4 years (n= 45), 22.4% had 5-10 
years (n=43), 13.5% had 11-15 years (n=26), 13.0% had 16-20 years (n=25).  The majority of 
participants held a Masters degree (n=145, 75.5%), 11.5% held a Bachelors degree (n= 22), and 
13.0% held a Doctorate degree (n=25).  The majority of participants deliver anesthesia in private 
hospitals (n=108, 56.3%) followed by public (county) hospitals (n= 53, 27.6%), outpatient 
surgical centers (n=29, 15.1%), and Veteran Affairs (V. A.) Hospitals (n=2, 1.0%).  Participants 
primarily delivered anesthesia in a non-academic facility (n=113, 58.9%) compared to an 
academic facility (n=79, 41.1%).   
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Table 3. Sociodemographics 
Variables Frequency Percentage 
How many years have you been a 
Certified Registered Nurse Anesthetist? 
0-4 years 45 23.4 
5 – 10 years 43 22.4 
11 – 15 years 26 13.5 
16 – 20 years 25 13.0 
> 20 years 53 27.6 
Total 192 100.0 
What is the highest degree you hold 
related to anesthesia? 
Bachelors 22 11.5 
Masters 145 75.5 
Doctorate 25 13.0 
Total 192 100.0 
What type of institution do you 
primarily administer anesthesia? 
Outpatient Surgical 
Center 
29 15.1 
Public (County) 
Hospital 
53 27.6 
Private Hospital 108 56.3 
V.A. Hospital 2 1.0 
Total 192 100.0 
How would you describe your 
anesthesia practice? 
Academic 79 41.1 
Non-academic 113 58.9 
Total 192 100.0 
I routinely reverse muscle paralysis. 
 
 
Agree 151 78.6 
Neutral 16 8.3 
Disagree 25 13.0 
Total 192 100.0 
Implementation of a best practice 
protocol for the reversal of 
neuromuscular blockade using 
neostigmine would be beneficial to my 
practice. 
Agree 114 59.4 
Neutral 51 26.6 
Disagree 27 14.1 
Total 192 100.0 
 
 Due to the heterogeneous nature of responses to the question, “How many years have you 
been a Certified Registered Nurse Anesthetist?,” the variables were grouped together to create 
two homogenous variables.  The new grouping includes the following variables: 0-10 years 
(n=88) and 11- 29 years (n=104) (Table 4).  Similarly, variables for the survey question, “What 
type of institution do you primarily administer anesthesia?,” were regrouped by combining 
variables “V.A Hospital” with “Public (County) Hospital.”.  The new grouping includes the 
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following variables: outpatient surgical center (n=29), public hospital (n=55), and private 
hospital (n=108) (Table 4). 
Table 4. Regrouped Variables 
Variables Frequency Percentage 
How many years have you 
been a Certified Registered 
Nurse Anesthetist? 
0 – 10 years 88 45.8 
11 – 29 years 104 54.2 
Total 192 100 
What type of institution do 
you primarily administer 
anesthesia? 
Private Hospital 108 56.3 
Public Hospital 55 28.6 
Outpatient Surgical Center 29 15.1 
Total 192 100 
 
Table 5. Survey Question Frequencies   
Variables Frequency Percentage M SD 
I routinely reverse muscle paralysis. 
 
 
Agree 151 78.6  
2.66 
 
0.699 Neutral 16 8.3 
Disagree 25 13.0 
Total 192 100.0 
I consider the age of the patient as an 
important factor in the administration of 
neostigmine. 
Agree 56 29.2  
1.88 
 
0.834 
 
Neutral 56 29.2 
Disagree 80 41.7 
Total 192 100.0   
Overall, I consider the number of muscle 
twitches present during train-of-four testing 
as an important factor in the administration 
of neostigmine. 
Agree 152 79.2  
2.68 
 
0.671 
 
Neutral 18 9.4 
Disagree 22 11.5 
Total 192 100.0  
Overall, I consider the quality of the muscle 
twitches during train-of-four testing as an 
important factor in the administration of 
neostigmine. 
Agree 158 82.3  
2.74 
 
0.601 Neutral 18 9.4 
Disagree 16 8.3 
Total 192 100.0  
I consider twitches with fade during train-
of-four testing as an important factor in the 
administration of neostigmine. 
Agree 146 76.0  
2.68 
 
0.622 Neutral 30 15.6 
Disagree 16 8.3 
Total 192 100.0  
I consider twitches without fade during 
train-of-four testing as an important factor 
in the administration of neostigmine. 
 
Agree 114 59.4  
2.45 
 
0.729 Neutral 51 26.6 
Disagree 27 14.1 
Total 192 100.0  
I consider the time elapsed since the last 
dose of neuromuscular blocking agent when 
administering neostigmine. 
 
Agree 168 87.5  
2.80 
 
0.553 Neutral 10 5.2 
Disagree 14 7.3 
Total 192 100.0   
I consider increasing the dose of 
neostigmine when the twitches have fade in 
train-of-four testing. 
Agree 105 54.7  
2.31 
 
0.834 Neutral 41 21.4 
Disagree 46 24.0
Total 192 100.0 
I consider decreasing the dose of Agree 89 46.4   
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neostigmine when the twitches have no fade 
in train-of-four testing. 
 
Neutral 50 26.0 2.19 0.841 
Disagree 53 27.6 
Total 192 100.0  
Overall, I consider the patient body mass 
index as an important factor for dosing of 
neostigmine. 
 
Agree 72 37.5  
2.03 
 
0.849 Neutral 54 28.1 
Disagree 66 34.4 
Total 192 100.0 
I routinely use subjective neuromuscular 
monitoring (i.e. Train-of-four, Tetanus) to 
assess patient readiness for reversal with 
neostigmine. 
Agree 165 85.9  
2.79 
 
0.549 Neutral 14 7.3 
Disagree 13 6.8 
Total 192 100.0 
I routinely use train-of-four nerve 
monitoring to assess patient readiness for 
reversal with neostigmine. 
 
Agree 167 87.0  
2.81 
 
0.518 Neutral 14 7.3 
Disagree 11 5.7 
Total 192 100.0  
I routinely use tetanus nerve monitoring to 
assess patient readiness for reversal with 
neostigmine. 
 
Agree 83 43.2  
2.12 
 
0.857 Neutral 49 25.5 
Disagree 60 31.3 
Total 192 100.0  
I routinely use objective neuromuscular 
monitoring (i.e. TOF Watch) to assess 
patient readiness for reversal with 
neostigmine. 
Agree 91 47.4  
2.15 
 
0.886 Neutral 38 19.8 
Disagree 63 32.8 
Total 192 100.0 
Implementation of a best practice protocol 
for the reversal of neuromuscular blockade 
using neostigmine would be beneficial to 
my practice. 
Agree 114 59.4  
2.45 
 
 
0.729 
 
Neutral 51 26.6 
Disagree 27 14.1 
Total 192 100.0  
 
 The body of the survey inquired if CRNAs “agree,” are “neutral,” or “disagree” with 
specific factors relating to the dosing and administration of neostigmine, and monitoring of 
neuromuscular blockade status to assess readiness for reversal.  Factors considered by CRNAs 
were defined as those questions having greater than 50% of the CRNAs selecting “agree.” 
Factors not considered by CRNAs are those with less than 50% of the CRNAs selecting “agree.”  
Factors considered by CRNAs include: number of muscle twitches present during train-of-four 
testing (agree=152, 79.2%; neutral=18, 9.4%; disagree=22,11.5%), quality of muscle twitches 
present during train-of-four testing (agree=158, 82.3%; neutral=18, 9.4%; disagree=16, 8.3%), 
twitches with fade (agree=146, 76.0%; neutral=30, 15.6%; disagree=16, 8.3%), twitches without 
fade (agree=114, 59.4%; neutral=51, 26.6%; disagree= 27, 14.1%), time elapsed since the last 
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dose of NMBA (agree=168, 87.5; neutral=10, 5.2%; disagree=14, 7.3%).  A factor considered by 
CRNAs was identified as increasing the dose of neostigmine when the twitches have fade 
(agree=105, 54.7%; neutral= 41, 21.4%; disagree= 46, 24.0).  Neuromuscular monitoring used 
by CRNAs when assessing patient readiness for reversal includes routine use of subjective 
neuromuscular monitoring (agree=165, 85.9%; neutral=14, 7.3; disagree=13, 6.8%) and routine 
use of train-of-four monitoring (agree=167, 87.0%; neutral=14, 7.3%; disagree=11, 5.7%).  
Factors not considered by CRNAs include age of the patient (agree=56, 29.2%; neutral=56, 
29.2%; disagree=80, 41.7%), patient body mass index (agree=89, 37.5%; neutral=54, 28.1; 
disagree=66, 34.4%), decreasing the neostigmine dose when twitches have no fade (agree=89, 
46.4%; neutral=50, 26.0%; disagree=53, 27.6%), routine use of tetanus nerve monitoring 
(agree=83, 43.2%; neutral=49, 25.5%; disagree=60, 31.3%), and routine use of objective 
neuromuscular monitoring (agree=91,47.4%; neutral=38, 19.8%; disagree=63, 32.8%). 
Inferential Statistics 
 A chi-square test was conducted to determine statistically significant associations 
between categorical variables in terms of years of CRNA experience, level of education, type of 
practice, and institutional setting and patient age when administering neostigmine.  No 
statistically significant associations were found between patient age and years of CRNA 
experience (Χ2 (2, N = 192) = 4.210, p = 0.122) or CRNA level of education (X2 (4, N = 192) = 
0.525, p = 0.971) or type of institution CRNA is employed (X2 (4, N = 192) = 4.841, p = 0.304) 
or type of practice (X2 (2, N = 192) = 2.648, p = 0.266).  
 Results from several survey questions were combined to create two variables:  
neuromuscular twitch monitoring and subjective nerve monitoring.  The neuromuscular twitch 
monitoring variable combines all survey questions regarding practitioner clinical decision 
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making in regards to twitch count and quality (questions 8, 9, 10, 11, 13, and 14).  The subjective 
nerve monitoring variable combines survey questions regarding the use of subject nerve 
monitoring including train-of four and tetanus (questions 16, 17, and 18).   
 An independent-samples t-test was conducted to compare years of CRNA experience and 
type of practice to neuromuscular twitch monitoring and the use of subjective nerve monitoring 
(i.e. TOF, twitch quality). There was no significant difference in the scores for 0-10 years of 
CRNA experience (M = 14.76, SD = 3.49) and 11-29 years of CRNA experience (M=15.27, 
SD=2.42), t(190) = -1.206, p = 0.229, compared to neuromuscular twitch monitoring practice.  
There was no significant difference in the scores for academic practice type (M = 14.93, SD = 
3.02) and non-academic practice type (M = 15.11, SD = 2.93), t(190) = -0.409, p = 0.683, 
compared to the use of subjective nerve monitoring.  There was no significant difference in the 
scores for 0 – 10 years of CRNA experience (M = 7.67, SD = 1.31) and 11-29 years of CRNA 
experience (M = 7.76, SD = 1.54), t(190) = -0.474, compared to the use of subjective nerve 
monitoring.  These results suggest that CRNA experience and type of practice are not influential 
factors in the practice of twitch interpretation or subjective neuromuscular monitoring practices. 
Test-retest Reliability 
 A total of 44 CRNAs volunteered to complete a retest survey, however only 28 
participants completed the retest, which contained identical survey questions to that of the 
original survey.  Using the Pearson correlation coefficient test the results of the original survey 
were correlated with the results of the retest. A statistically significant correlation was revealed 
between the two surveys (r = 0.84, p < 0.000), thereby providing adequate evidence of test-retest 
reliability. 
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Section V: Discussion 
 This study is the first investigation that assessed the various factors that CRNAs use in 
NMB reversal with neostigmine. Moreover, the differences in factors considered by CRNAs 
were also examined for statistically significant associations in terms of the years of CRNA 
experience, level of education in anesthesia, type of practice, and institutional setting. First, there 
were no statistically significant difference between years of CRNA experience and consideration 
of patient age when reversing neuromuscular blockade with neostigmine.  Second, there was no 
statistically significant difference between years of CRNA experience, CRNA level of education, 
type or practice and type of institution when compared to the use of neuromuscular twitch 
monitoring, and use of subjective nerve monitoring.  Overall, no statistically significant 
differences were found in the mean score of the factors considered for neostigmine use between 
CRNAs in terms of years of experience, types of practice, institutional settings, and levels of 
education.  These findings reconfirm the discord present in the practice of NMB reversal, which 
was noted in previous studies (Naguib et al., 2010; Videira & Vieira, 2011). 
 This study also assessed the factors considered by CRNAs when dosing and 
administrating neostigmine, and monitoring of neuromuscular blockade status to assess readiness 
for reversal.  Factors reportedly considered by CRNAs when administering neostigmine include: 
number and quality of muscle twitches present during train-of-four testing, twitches with fade, 
twitches without fade, and time elapsed since the last dose of NDMR.  These factors include the 
eight most commonly used factors used for reversal of NDMR identified by Videira and Vieira 
(2011).  One factor considered by CRNAs when dosing neostigmine is increasing the dose of 
neostigmine when the TOF demonstrate fade.  According to Kopman and Eikermann (2009), 
management of a twitch count of four with fade requires an increased dose of neostigmine 
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(0.04mg/kg) compared to a twitch count of four without fade (0.02mg/kg).  Nerve monitoring 
used by CRNAs when assessing patient readiness for reversal includes routine use of subjective 
nerve monitoring and routine use of train-of-four monitoring.  Anesthesia providers in the US 
commonly use subjective nerve monitoring (includes train-of-four-monitoring) (Naguib et al., 
2010).  Factors not commonly used by CRNAs included age of the patient, patient body mass 
index, decreasing neostigmine dose when twitches have no fade, routine use of tetanus nerve 
monitoring, and routine use of objective neuromuscular monitoring. 
 This study defined factors used by CRNAs when deciding to reverse NMB as those 
having a percentile greater than 50%, however there was significant disagreement amongst 
CRNAs regarding these factors. The results of this study duplicate the studies by; Duvalestin, 
Cunin, Plaud, and Maison (2008), Gray & Wilson (1959), Naguib et al. (2010), and Videira and 
Vieira (2011) which identified a large variation in the practice of dosing and administering 
neostigmine amongst anesthesia providers.  Evidenced by the overwhelming lack of statically 
significant data this study highlights the dissonance present amongst anesthesia providers in the 
dosing and administration practices of neostigmine.  With residual NMB affecting upwards of 
40% of post-operative patients who received intra-operative neuromuscular blocking agents, it is 
evident that the current practice of neostigmine use is inadequate (Murphy & Brull, 2010).  A set 
of universally excepted evidence-practice guidelines for the reversal of NMB with neostigmine is 
necessary to aid anesthesia providers in safe and consistent NMB reversal practices. 
 Residual NMB occurs far too often in post-operative patients and results in an increased 
morbidity and mortality.  As seen in the results of this study, the current practice of reversing 
muscle paralysis remains unstandardized resulting in a large variation in the practice of dosing 
and administering neostigmine, and NMB status when reversing with neostigmine.  This 
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unstandardized approach promotes residual NMB and endangers patient safety and should be 
addressed immediately. 
Limitations 
 Limitations of the study were identified.  First, the survey tool did not include a gender 
differentiation question.  Analyzing variances between genders is typically standard, albeit there 
is no difference in the clinical training or didactic course work between male and female nurse 
anesthetists, therefore it is unlikely gender has a role in dosing and administering neostigmine.  
Second, this survey had a small population and was restricted only to CRNA members of IANA; 
excluded were attending anesthesiologists, anesthesia residents, and SRNAs, thereby limiting 
generalizability of study findings to the overall anesthesia provider population.  Future studies on 
this topic could include these anesthesia providers populations. Third, the study focused only on 
the most commonly used cholinesterase inhibitor, neostigmine; results must be interpreted with 
caution as there are other agents being used in the clinical setting. 
Recommendations 
 Development of a universally accepted evidence-based practice protocol for the reversal 
of NMB using neostigmine is necessary to improve patient safety and reduce post-operative 
morbidity and mortally related to residual NMB.  The evidence obtained from this study was be 
used to develop an evidence-based protocol for the safe reversal of NMB.  A protocol 
incorporating key factors in the reversal of NMB identified in this study is outlined below. The 
investigators of this study plan to submit this protocol to the IANA and/or the AANA for white 
paper consideration. 
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Evidence-based Guidelines -  
Neuromuscular Blockade Reversal With Neostigmine   
TOF 0 – 1 Twitch 2-3 twitches 4 Twitches w/ Fade 4 Twitches w/o Fade 
TOF Ratio   TOFR < 0.4 TOFR ≥ 0.4 
Neostigmine Wait on Reversal Administer 50mcg/kg3 Administer 40 mcg/kg3 Administer 20 mcg/kg3
Timing N/A 15-30 min before 
extubation2 
15-30 min before 
extubation2 
15-30 min before 
extubation2 
Clinical Considerations: 
Neostigmine: 
 Dose: 20-50 mcg/kg3 
 Administer concomitantly with 
anticholinergic (i.e Glycopyrrolate)11 
 No reversal recommended for TOFR ≥ 0.9  
 Obesity9 and increased age10 lengthens 
reversal time to TOF ratio ≥ 0.9 
 
Monitoring: 
 Monitoring is a standard of care1 
 Objective monitoring is preferred over subjective as 
it most reliably monitors status of NMB1, 12 
 The preferred site for peripheral nerve stimulation is 
the adductor pollicis13 (ulnar nerve stimulation). 
 Do not rely on clinical signs/test (i.e. headlift, hand 
grasp, eye opening) as they do not accurately 
represent status of neuromuscular recovery4,5,6,7 
1(Brull & Murphy, 2010), 2(Murphy, 2006), 3(Kopman & Eikermann, 2009), 4(Eikermann, Groeben, Hussing, & 
Peters, 2003), 5(Hayes, Mirakhur, Breslin, Reid, & McCourt, 2001), 6(Fruergaard, Mogensen, Berg, & El Mahdy, 
1998), 7(Mogensen & Claudius, 2010), 8(Buder, 2010), 9(Suzuki, Masaki, Ogawa, 2006), 10(Bevan, et al., 1999), 
11(Butterworth, Mackey, & Wasnick, 2013a), 12(Murphy et al., 2008), 13(Thilen et al., 2012) 
 
 It is important to note that improvement of the practice of neuromuscular blockade 
reversal is not a substitute for interdisciplinary communication.  In fact, effective communication 
is equally as important as following the evidence-based practice guidelines.  There has to be an 
exchange of communication between the anesthesia provider and the surgeon to assess post-
operative plans, estimated duration to the end of surgery, and whether maintenance of 
neuromuscular blockade is required throughout the case.  Each of these discussion points has the 
potential to affect the neuromuscular blockade plan, and if proper communication does not take 
place there is an increased risk of harm to the patient. 
Implications for Future Research 
 This study defers the evaluation process for future research.  After initiation of the 
evidence-based guidelines for neuromuscular blockade reversal with neostigmine at the 
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institutional, state, or national level, evaluation of possible change in practice could take place.  
Resubmission of the survey tool (Appendix C) to the same population would allow for 
comparisons between neuromuscular block reversal practices pre-EBP protocol and post.  In 
addition, surveillance of residual neuromuscular blockade incidence rates could assess the effects 
of practice change, although this issue is multifactorial and it may be difficult to determine the 
cause of any incidence rate changes.  Additional follow-up studies could include additional 
anesthesia providers including attending anesthesiologists, anesthesia residents, and student 
nurse anesthetists.  Furthermore, these follow up studies should compare the dosing and 
administration practices of neostigmine between attending anesthesiologists, anesthesia residents, 
student nurse anesthetists, and CRNAs.   
Conclusion 
 This study described the various factors used by CRNAs when dosing and administering 
neostigmine.  There are no significant associations in any of these factors with CRNAs' 
subgroupings according to their years of anesthesia experience, level of education in anesthesia, 
type of practice, and institutional setting.  The overall factors used by CRNAs include the 
number and quality of muscle twitches present during train-of-four testing, twitches with and 
without fade, time elapsed since the last dose of NDMR, increased dosing of neostigmine when 
the twitches have fade, and routine use of subjective neuromuscular monitoring, including TOF.   
 Residual neuromuscular blockade occurs far too often in post-operative patients and 
results in an increased morbidity and mortality.  The current practice of reversing muscle 
paralysis is not standardized, resulting in a large variation in the neostigimine dosing practice, 
and evaluation of NMB status when reversing with neostigmine.  This nonstandardized approach 
promotes residual NMB and endangers patient safety.  This study presented a set of evidence-
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based guidelines with the goal of standardizing NMB reversal.  The standardization of practices 
related NMB reversal will improve patient safety and reduce the incidence of residual 
neuromuscular blockade. 
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Table 1. Synthesis of the Adverse Effects of Residual Neuromuscular Blockade 
Authors & Year Purpose Design Sample/Population Statistical 
Analysis 
Findings 
(Debaene, Plaud, Dilly, 
& Donati, 2003) 
Evaluate incidence of 
residual paralysis 
(TOF Ratio < 0.9) in 
the PACU after a 
single intubating dose 
of an intermediate-
acting NDMR is 
administered at a 
dosage twice the 
ED95. 
-Non-
randomized, 
observational 
study. 
-Anesthetic 
management was 
provider specific. 
-Groups: 
-Vecuronium 
-Rocuronium 
-Atracurium 
-526 patients 
 
-No mention of IRB or 
ethics committee 
approval. 
-Probability 
values were 
used to reject 
null 
hypothesizes. 
-No other 
statistical 
calculations 
were reported. 
-Patients with a TOF ratio <0.7: 16% 
-Patients with a TOF ratio < 0.9: 45% 
-10% of patients had a TOF ratio <0.7 2 
hours or more after administration of MR. 
-Traditional clinical tests (head lift, tongue 
depressor) and manual assessment of twitch 
fade demonstrated a poor sensitivity to detect 
residual block (11-14%). 
(Cedborg et al., 2014) Evaluate the effects 
of partial NMB on 
pharyngeal function, 
coordination of 
breathing and 
swallowing, and 
airway protection in 
the elderly. 
-Non-
randomized, 
controlled Study. 
-Study intervals: 
TOF 0.7, 0.8, 
and >0.9 
 
Study Group: 17 
volunteers over 65 years 
old  
Control Group: 6 
volunteers over 65 years 
old 
-Local Ethics Board 
Approved. 
-ANOVA 
-Generalized 
linear model 
-Wilcoxon test  
-Mann-
Whitney U test 
-Positive correlation between partial NMB 
and increased pharyngeal dysfunction. 
-No correlation between partial NMB and 
coordination of breathing and swallowing. 
(Hayes, Mirakhur, 
Breslin, Reid, & 
McCourt, 2001) 
Compare incidence 
of postoperative 
residual NMB in 
patients entering the 
PACU after use of 
intermediate-acting 
NMBDs.  
-Randomized, 
controlled study 
-Provider 
unaware that 
patient is in 
study. 
-Four Groups: 
-Control 
-Vecuronium 
-Atracurium 
-Rocuronium 
-Data collected 
on randomized 
days. 
-160 patients 
-LRB Approved 
-Written and informed 
consent obtained 
-One-way 
ANOVA 
-Kruskal-
Wallis test 
-Chi-squared 
Test 
 
-A large proportion of patients entering the 
PACU, whom have received intermediate-
acting NMBDs, have a TOF ratio < 0.8. 
(Murphy et al., 2008) 1) Compare 
effectiveness of 
objective 
-Randomized, 
controlled, single 
blind Study 
-185 patients undergoing 
elective surgery requiring 
intraop NMB. 
-One-sided 
Chi squared 
test 
-Intraoperative management of NMB did not 
differ significantly. 
-No statistical significance of the time from 
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neuromuscular 
monitoring on the 
incidence of 
postoperative residual 
NMB with qualitative 
monitoring. 
2) Effect of 
intraoperative 
objective monitoring 
on postop hypoxemia 
and airway 
obstruction. 
-Groups: 
-
Acceleromyo-
graphy group 
-Conventional 
TOF Group 
(control). 
-Standardized 
anesthetic 
management 
-IRB approved 
-Written and informed 
consent obtained 
-Fisher exact 
probability test 
-Mann-
Whitney U test 
-Spearman 
Rank 
Correlation 
Coefficient 
administration of reversal to extubation. 
-A significantly higher incidence of TOF 
ratio <0.7 occurred in the conventional 
group. 
(Sundman et al., 2000) 1) Evaluate 
swallowing using 
fluoroscopy to record 
and understand the 
mechanism behind 
pharyngeal 
dysfunction during 
partial NMB. 
2) Evaluate the 
effects of Atracurium 
on pharyngeal 
function. 
-Non-
randomized, 
controlled Study. 
-A total of 444 
swallows 
analyzed. 
-Counted each 
swallow as 1 
data point & 
Compared TOF 
ratio (0.6, 0.7, 
0.8, > 0.9) to 
area of 
penetration 
(pharynx, larynx, 
or bolus 
remained in 
mouth)  
Sample Size: 20 healthy 
volunteers (12 men, 8 
women) 
-LRB approved 
 
-Regression 
-T-test 
-Wilcoxon 
signed rank 
test 
-Partial NMB by Atracurium is associated 
with an increased incidence of misdirected 
swallowing. 
-The MOA of pharyngeal dysfunction was 
identified as a delayed initiation of the 
swallowing reflex, impaired function of 
pharyngeal muscles, and impairment of 
coordination. 
-The majority of misdirected boluses 
penetrated the laryngeal inlet. 
(Suzuki, Masaki, & 
Ogawa, 2006) 
Compare reversal of 
vecuronium by 
neostigmine in 
normal weight, 
overweight, and 
obese female 
patients. 
Non-
randomized, 
controlled study. 
-Three Groups: 
-Normal 
Weight 
-Overweight 
-Obese 
-Normal weight 
group is control. 
-45 female patients. 
-ASA physical status I or 
II 
-Age 27-57 years old 
-Elective gynecologic 
surgery. 
-Approval by Hospital 
Ethics Committee on 
Human Rights in 
Research. 
-ANOVA 
-Bonferroni 
post hoc test 
-When using RBW to dose vecuronium, 
recovery to a TOF ratio of 0.9 is slow in 
overweight and obese (female) patient 
population. 
-Time to TOF ratio of 0.9: 
- Obese: 25.9 minutes 
-Overweight: 14.6 minutes 
-Normal Weight: 6.9 minutes 
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-Vecuronium 
dosing using real 
body weight 
(RBW). 
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Appendix A. Letter to IANA Administrator 
 
Dear IANA Administrator, 
 
My name is Kyle Mayer and I am a Nurse Anesthesia Trainee from DePaul University and 
NorthShore University School of Nurse Anesthesia.  I am conducting a research study on the 
current practice of dosing and administration of the neuromuscular blockade reversal agent, 
neostigmine.  I am writing to request an email containing a web link to the survey be emailed to 
all CRNA members of the IANA. 
 
Participation in the study is voluntary.  All responses are anonymous and IP addresses will not be 
tracked.  
 
I have attached the email message with the link to the survey.  The survey is now available and 
the survey invitation email can be distributed at your soonest convenience.  Please contact me 
with any questions or concerns.   
 
Thank you very much.  
 
Sincerely, 
 
Kyle Mayer, BSN, RN, NAT 
DePaul University 
NorthShore University – School of Nurse Anesthesia 
mayerkyle427@hotmail.com 
 
 
Attachment: (See Appendix B) 
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Appendix B. Email Template for Survey Dissemination 
 
Dear Illinois CRNA, 
 
My name is Kyle Mayer and I am a Nurse Anesthesia Trainee from DePaul University.  I am 
writing to invite you to participate in my research study regarding the current practice of 
neuromuscular blockade reversal dosing and administration.  This study is only available to 
members of the Illinois Association of Nurse Anesthetists.  
 
All responses are anonymous and IP addresses will not be tracked.  Study participation is 
completely voluntary, and it will take about 5 minutes of your time to complete the survey. If 
you would like further details regarding this study, I have attached a study information sheet.   
 
If you'd like to participate in this study please click the following link – 
http://depaul.qualtrics.com/SE/?SID=SVcPatJOquqcRYRtr 
 
Thank you very much.  
 
Sincerely, 
 
Kyle Mayer, BSN, RN, NAT 
DePaul University 
mayerkyle427@hotmail.com 
	
	
Attachment: Study Information Sheet 
	
  
NEOSTIGMINE 47
Appendix C.  Survey of the Current Practice of Muscle Paralysis Management and Reversal 
 
1. You are invited to participate in a web-based online survey on the development of practice 
guidelines for the reversal of neuromuscular blockade using neostigmine.   Your participation 
in this survey is voluntary. You may refuse to take part in the research or exit the survey at 
any time without penalty. You are free to decline to answer any particular question you do 
not wish to answer for any reason.  
 
This online survey will not collect identifying information such as your name, email 
address, or IP address; therefore, your responses will remain anonymous.  If you agree to 
participate in the second follow-up survey, we will ask for your email address in order to 
send you another survey. In this case your responses will not be anonymous, but we will 
keep them confidential. 
 
Consent: If you would like to take part in this brief survey click “Accept.”  If you choose 
to not participate in this survey click “Decline,” and close your browser window. 
 
     Accept     Decline 
 
2.  How many years have you been a Certified Registered Nurse Anesthetist? 
 
 0-4          5-10          11-15            16-20             >20  
 
3.  What is the highest degree you hold related to anesthesia? 
 
 Bachelors                  Masters                  Doctorate                       
 
4.  What type of institution do you primarily administer anesthesia? 
 
 Outpatient Surgical Center     Public (County) Hospital    Private Hospital     VA Hospital 
 
5. How would you describe your anesthesia practice? 
 
 Academic  Non-academic 
 
6.  I routinely reverse muscle paralysis. 
 
 Disagree        Neutral        Agree         
 
7.  I consider the age of the patient as an important factor in the administration of neostigmine. 
 
 Disagree        Neutral        Agree         
 
8.  Overall, I consider the number of muscle twitches present during train-of-four testing as an 
important factor in the administration of neostigmine. 
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 Disagree        Neutral        Agree         
 
9.  Overall, I consider the quality of the muscle twitches during train-of-four testing as an 
important factor in the administration of neostigmine. 
 
      Disagree        Neutral        Agree         
 
10.  I consider twitches with fade during train-of-four testing as an important factor in the 
administration of neostigmine. 
 
      Disagree        Neutral        Agree         
 
11.  I consider twitches without fade during train-of-four testing as an important factor in the 
administration of neostigmine. 
 
      Disagree        Neutral        Agree         
 
12.  I consider the time elapsed since the last dose of neuromuscular blocking agent when 
administering neostigmine. 
 
      Disagree        Neutral        Agree         
13. I consider increasing the dose of neostigmine when the twitches have fade in train-of-four 
testing. 
 
      Disagree        Neutral        Agree         
 
14.  I consider decreasing the dose of neostigmine when the twitches have no fade in train-of-
four testing. 
 
      Disagree        Neutral        Agree         
 
15.  Overall, I consider the patient body mass index as an important factor for dosing of 
neostigmine. 
 
        Disagree        Neutral        Agree         
 
 
16. I routinely use subjective neuromuscular monitoring (i.e. Train-of-four, Tetanus) to assess 
patient readiness for reversal with neostigmine. 
 
      Disagree        Neutral        Agree         
 
17.  I routinely use train-of-four nerve monitoring to assess patient readiness for reversal with 
neostigmine. 
 
      Disagree        Neutral        Agree         
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18.  I routinely use tetanus nerve monitoring to assess patient readiness for reversal with 
neostigmine. 
    Disagree        Neutral        Agree         
 
19.  I routinely use objective neuromuscular monitoring (i.e. TOF Watch) to assess patient 
readiness for reversal with neostigmine. 
 
      Disagree        Neutral        Agree         
 
20.  Implementation of a best practice protocol for the reversal of neuromuscular blockade using 
neostigmine would be beneficial to my practice. 
 
     Disagree        Neutral        Agree         
 
 
****************************New Page**************************** 
 
 
Would you be willing to take the same survey again in 1 week to assess consistency of survey 
responses?  
 
 YES (Repeat survey link will be sent in 1 week) 
  If YES, please type your email address:________________________ 
 
 NO (no repeat survey link will be sent) 
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Appendix D. Email Template for Test/Re-test Survey Validity 
 
Dear Illinois CRNA, 
 
My name is Kyle Mayer and I am a Nurse Anesthesia Trainee from DePaul University.  I am 
writing you because you recently participated in a research and volunteered to retake a portion of 
the survey.  As a reminder, the research study is regarding the current practice of neuromuscular 
blockade reversal dosing and administration.  
 
Again, all responses are anonymous and IP addresses will not be tracked.   Study participation is 
completely voluntary; you have the choice to participate in this study or to not.  If you'd like to 
participate in this follow up survey please click the following link – [weblink to survey]. 
 
Thank you very much.  
 
Sincerely, 
 
Kyle Mayer, BSN, RN, NAT 
DePaul University 
mayerkyle427@hotmail.com 
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Appendix E. SLP Committee Members 
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Appendix F. IRB Approval Letter 
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Appendix G. SLP Final Approval Form 
 
